Today, Intomics A/S and LEO Pharma A/S announced a collaboration under which LEO Pharma gains access to Intomics’ unique biological data analysis expertises. The recently founded spin-off company from The Danish Technical University, Intomics, has methods and tools for use in LEO Pharma’s early drug discovery. The collaboration spans a range of research projects. The financial terms of the agreement were not disclosed.

“We are extremely pleased to be working with LEO Pharma on their discovery projects. Using our unique expertise and state-of-the-art biological data analysis technologies, we can facilitate fast, efficient research projects with improved results for LEO Pharma” says Thomas S. Jensen, founder and CEO of Intomics and continues, “Today, research projects generate large amounts of biological data, and sophisticated analyses of these are required to optimize the success rate of research projects. To facilitate this, both highly specialized know how and advanced tools are required. The synergy between LEO Pharma’s research in dermatology and critical care, and Intomics’ expertise in advanced biological analyses, will help face this challenge and lead to better, safer drugs - and ultimately benefit patients in these important areas.”

About LEO Pharma A/S:

LEO Pharma is an independent, research-based pharmaceutical company based in Ballerup, Denmark, near Copenhagen. LEO Pharma is wholly owned by the LEO Foundation and is one of the world’s leading companies within dermatology (skin diseases) and the parenteral treatment of thromboembolisms (thrombosis). For more information, please see http://www.leo-pharma.com.

About Intomics A/S:

Intomics is a contract research company with leading expertise in biological data analysis & data mining, bioinformatics and systems biology. Using pioneering technologies, Intomics provide tailored solutions leading to increased success rates and cost savings in pharmaceutical research projects.